Receive updates from Biotech Investments for free, starting right now.
We can deliver them by email, via your phone or you can read them from a personalised news page on follow.it.
This way you won't miss any new article from Biotech Investments. Unsubscribe at any time.
Site title: Biotech Investments – Independent Medical Rating Agency for Biotech and Pharmaceutical Assets. Purpose-built for Investors and Industry Partners.
Is this your feed? Claim it!
Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatment
BRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration tre...
EQS Newswire / 12/06/2026 / 15:02 UTC+8
Shanghai – 12 Jun 2026 – The clinical datasets presented at ASCO 2026 further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy.
...